Skye Bioscience, Inc. Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock - Warrants (Detail Textuals 2) - USD ($)	1 Months Ended
	Jan. 31, 2018	Feb. 28, 2017	Jan. 31, 2017	Dec. 31, 2016	Dec. 29, 2016
Equity [Line Items]
Warrant exercise price (in dollars per share)				$ 0.25
Series D Preferred Stock [Member]
Equity [Line Items]
Warrant exercise price (in dollars per share)				$ 0.25	$ 0.25
Warrants
Equity [Line Items]
Number of warrants issued		125,000
Warrant exercise price (in dollars per share)		$ 0.41
Term of warrant		5 years
Value of common stock called by warrants		$ 30,000
Warrants \| Series D Preferred Stock [Member]
Equity [Line Items]
Number of warrants issued			480,000
Warrant exercise price (in dollars per share)			$ 0.25		$ 0.25
Term of warrant			5 years
Value of common stock called by warrants			$ 115,200
Warrants \| Securities purchase agreement
Equity [Line Items]
Number of warrants issued	44,200,000
Warrant exercise price (in dollars per share)	$ 0.10
Term of warrant	5 years